Now offering custom senolytic compound development and clinical study services - The Senescence Challenge
Cellular senescence – the process by which cells lose their ability to divide and function properly – is a fundamental driver of aging and age-related diseases. These “zombie cells” accumulate in tissues over time, secreting inflammatory factors that accelerate aging and contribute to conditions ranging from arthritis to cardiovascular disease.
Revolutionary Screening Technologies
Senolytine™ employs cutting-edge bioinformatics and transcriptome analysis to identify senescence-specific targets. By comparing RNA sequencing data from senescent versus normal cells, we’ve identified key survival networks that keep aging cells alive despite their dysfunction.
CRISPR-Cas9 Functional Genomics
Our whole-genome screening approach uses CRISPR-Cas9 technology to systematically knock down genes and identify those whose inactivation selectively eliminates senescent cells while sparing healthy ones. This precision approach has led to the discovery of novel senolytic targets beyond the well-known BCL-2 family.
Comprehensive Compound Library
With over 1000 senolytic compounds in our library, Senolytine™ represents the world’s most extensive collection of senescence-targeting natural products. Key compounds include:
Fisetin: The Flavonoid Pioneer
This natural flavonoid has shown remarkable ability to clear senescent cells in multiple tissue types, with clinical trials demonstrating improved physical function in elderly adults.
Quercetin: The Versatile Senolytic
Combined with dasatinib in clinical studies, quercetin has proven effective in reducing senescent cell burden and improving healthspan markers.
Piperlongumine: The Selective Eliminator
This alkaloid from long pepper shows exceptional selectivity for senescent cells, making it a promising candidate for therapeutic development.
Clinical Translation and Biomarker Development
Our clinical study services include comprehensive biomarker panels measuring SASP factors, specific miRNAs, and aging-related transcripts. These tools are essential for evaluating senolytic efficacy in human trials and advancing regulatory approval.
The Future of Healthy Aging
As the first generation of senolytic drugs enters clinical practice, Senolytine™ is positioned to lead the next wave of natural, safer alternatives that could transform how we approach aging and age-related disease.